InMed Pharmaceuticals (INM) Profit After Tax (2019 - 2026)

InMed Pharmaceuticals has reported Profit After Tax for 8 years, with the latest figure at -$2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 31.63% year-over-year to -$2.8 million; the trailing twelve-month figure through Mar 2026 stood at -$8.4 million (changed 0.28% YoY), and the FY2025 full-year result was -$8.2 million, down 6.83% from the prior year.
• Profit After Tax for Q1 2026 stood at -$2.8 million, down from -$2.0 million in the prior quarter.
• The five-year high for Profit After Tax was -$347622.0 in Q2 2023, with the low at -$7.9 million in Q2 2022.
• Historically, Profit After Tax has averaged -$2.5 million across 5 years, with a median of -$2.0 million in 2025.
• Annual changes were most pronounced in 2023 — Profit After Tax jumped 95.58% — and 2024, when it plunged 468.3%.
• InMed Pharmaceuticals' Profit After Tax stood at -$2.1 million in 2022, then climbed by 29.65% to -$1.5 million in 2023, then slumped by 74.2% to -$2.6 million in 2024, then advanced by 21.23% to -$2.0 million in 2025, then plunged by 37.65% to -$2.8 million in 2026.
• The last three Profit After Tax figures came in at -$2.8 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.